BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
Journal for ImmunoTherapy of Cancer · 2025-05 · 13 (5) · e010073
DOI: 10.1136/jitc-2024-010073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.05.2025. Verfasst von Huihui Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of M…. Hauptthemen laut MEDLINE: Sulfonamides, Small Cell Lung Carcinoma, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Multi-disciplinary Treatment Project for Major Diseases, China Postdoctoral Science Foundation, Shanghai Chest Hospital Basic Research Project.
Abstract (Originalsprache)
Background
Patients with small cell lung cancer (SCLC) generally have a poor prognosis, with an exceptionally high proliferative rate and a strong propensity for early metastasis, indicating the urgent need for novel therapies. The development of chimeric antigen receptor (CAR)s targeting solid tumors is limited owing to the lack of target antigens and low efficacy. In this study, we aimed to discover new targets for SCLC CAR-T therapy and develop CAR-T-based combinational treatment against SCLC in preclinical models.
Methods
The in vitro antitumor activity of B7H6-specific CAR-T cell was evaluated. Venetoclax-resistant B7H6 CAR-T cell were designed and the synergistic effect of venetoclax and B7-H6 CAR-T cells was tested in vitro and in vivo.
Result
B7H6 is highly expressed in SCLC tumors. CAR-T cell against B7H6 displayed antigen-specific antitumor efficacy. BCL-2(D103E)-expressing CAR-T cells showed resistance to venetoclax-induced apoptosis. The combinational treatment of venetoclax and BCL-2(D103E)-expressing B7H6-targeting showed potent anti-SCLC effect in vitro and in vivo.
Conclusions
Our findings suggest that the combination of BCL-2 mutant-expressing B7H6-targeting CAR-T cells and venetoclax could be a promising novel strategy against B7H6-expressing SCLCs and other solid tumors, providing the foundation for CAR-T cells and proapoptotic small molecules therapy in patients with SCLCs in a clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
- Faculty of Art & Science, University of Toronto, Toronto, Ontario, Canada.
- Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China shunlu@sjtu.edu.cn xuanmingyang@sjtu.edu.cn.
- Joint International Research Laboratory of Metabolic and Developmental Sciences, Shanghai Jiao Tong University, Shanghai, China.
- Department of Gynaecology and Obstetrics, Shanghai Pudong New Area people's Hospital, Shanghai, China.
Förderung
- National Multi-disciplinary Treatment Project for Major Diseases
- China Postdoctoral Science Foundation
- Shanghai Chest Hospital Basic Research Project
- Ministry of Education
- National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Xia, L., Xuzhang, W., Li, Z., Zhang, J., Li, F., Cheng, C., Wang, J., Zong, X., Yang, X., & Lu, S. (2025). BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer. Journal for ImmunoTherapy of Cancer, 13(5), e010073. https://doi.org/10.1136/jitc-2024-010073
Vancouver
Zhang H, Xia L, Xuzhang W, Li Z, Zhang J, Li F, et al. BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer. Journal for ImmunoTherapy of Cancer. 2025;13(5):e010073. doi:10.1136/jitc-2024-010073
BibTeX
@article{Zhang2025,
author = {Zhang, Huihui and Xia, Liliang and Xuzhang, Wendi and Li, Ziming and Zhang, Junshi and Li, Fanlin and Cheng, Chen and Wang, Jiawen and Zong, Xincheng and Yang, Xuanming and Lu, Shun},
title = {BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {5},
pages = {e010073},
doi = {10.1136/jitc-2024-010073}
}
EUVIMED